Google
MLTX — MOONLAKE IMMUNOTHERAPEUTICS (Healthcare >> Biotechnology)
MLTX FAQ
What is MLTX's ROE?
MOONLAKE IMMUNOTHERAPEUTICS reports a Return on Equity (ROE) of -101.20%.
What is MLTX's dividend yield?
MOONLAKE IMMUNOTHERAPEUTICS offers a dividend yield of 0.00%.
What is MLTX's Deepscope Quality Score?
Deepscope rates MLTX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MLTX?
Deepscope's AI Timing Score for MLTX is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MLTX belong to?
MOONLAKE IMMUNOTHERAPEUTICS is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 17.90
Price
-0.82
(-4.38%)
Day Change
|
|
|---|
MLTX, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 85 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 17.90 |
| PBV / Sector |
5.29 / 4.63
|
| Earning Per Share | -3.42 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
16.64 M
GREAT
|
| Average 1W Daily Value |
11.98 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:03 |
| Symbol | MLTX |
| Name | MOONLAKE IMMUNOTHERAPEUTICS |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 73.62 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,344.95 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Dorfstrasse 29, Zug, Switzerland, 6300
Phone: 41 415108022
Website: https://www.moonlaketx.com
Employees: 130
Sector: Healthcare >> Biotechnology
Description: MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
